COST-EFFECTIVENESS ASSUMPTIONS "REASONABLE" AT "SOME POINT"; CE ANALYSES SHOULD AVOID USING ASSUMPTIONS IN MAKING MAJOR CONCLUSIONS -- FDA's WOODCOCK
Executive Summary
Cost-effectiveness analyses could include a point at which assumptions based on indirect evidence would be acceptable, FDA Center for Drug Evaluation & Research Director Janet Woodcock, MD suggested Nov. 26 at the Department of Health and Human Services' Workshop on Cost-Effectiveness. The workshop was held to examine the recent guidelines developed by the Panel on Cost-Effectiveness in Health and Medicine ("The Pink Sheet" Aug. 5, T&G-16).